What’s scaling, who’s paying, and why you should care
Let’s start with a question.
What do Oura, Sword Health, and Doctolib have in common?
If you said “healthtech unicorns” you’re technically right, but that’s not the real answer.
The real answer: they’re European, they’re growing like weeds, and most investors or founders still talk about them like they’re niche side projects.
Which is odd. Because these are the companies quietly shaping the future of healthcare on the old continent, while half the market’s still arguing about whether DiGA is dead or just very German.
So, I’ve put together something to help.
This is Mapping the European HealthTech Goldmine.
A five-part series for anyone building, backing, or expanding healthtech in Europe.
Why now?
Because the money’s back.
After the hangover that was 2023, last year saw European healthtech bounce to around $4.8 billion in VC funding. This year? $4.3 billion in Q1 alone, and that’s not even counting what gets tucked into medtech, diagnostics, or things with “AI” bolted on just to close a round.
The capital is flowing. But, and this is where it gets interesting, it’s not flowing evenly.
It’s going to:
- A handful of markets (Finland? Really? Yes.)
- A small set of models (wearables, MSK, diagnostics-as-a-service)
- And companies that figured out how to integrate with public health systems without losing their will to live.
What you’ll actually get
No vague “trends”. No breathless “disruption” language, this you have in the name of this website. I offer just five posts that get to the point:
- The Top 10 Most Valuable HealthTech Companies in Europe
Valuation league table, explained, and why some are quietly stalling. - Who’s Funding the Boom?
The VCs, public funds, and CVCs writing cheques in 2025. - 2024 vs 2025: Where the Money’s Really Coming From
VC vs grants vs corporate with actual (well, approximated) numbers. - Best Places to Launch or Scale a HealthTech Company in Europe
Spoiler: it’s not always Berlin or London. - What Europe’s HealthTech Winners Did Differently
(Besides surviving long enough to be acquired.)
Who this is for
If you’re a founder, an investor, or someone trying to scale something in European healthcare without losing your shirt — this is for you.
Especially if you’re tired of reading loud headlines about $20M Series A rounds in the US and wondering why your reimbursement pilot takes 18 months and a PowerPoint deck for the bored Ministry officials.
Read it, steal ideas from it, or forward it to your CFO
The first post, the top 10 most valuable healthtech companies in Europe goes live next.
After that, one post a week, give or take.
Short reads. Linked data. Unapologetically European perspective.
If that sounds useful, subscribe, bookmark, or just come back with coffee.
See you in the series.
